Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2023-08-30 Director's Dealing
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Notification of primary insider transaction
Director's Dealing Classification · 100% confidence The document is titled 'Photocure ASA: Notification of primary insider transaction' and explicitly states that a 'Primary insider notification pursuant to the market abuse regulation article 19 is attached.' It details a transaction (acquisition of shares) by a Board member, Dylan Hallerberg. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Category Mapping: - Director's Dealing (Code: DIRS): Report of personal share transactions by company directors and executives (insider trades). Given the content, DIRS is the most appropriate classification. The document length is short (1267 chars) and it refers to an attachment, but the core content *is* the notification itself, not just an announcement of a separate report, making DIRS more specific than RPA or RNS.
2023-08-30 English
Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Press Release" and announces a significant clinical trial milestone: Photocure's partner Asieris confirmed that the Hexvix Phase III clinical trial in China met its primary endpoint. This type of announcement, detailing operational or clinical progress rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it focuses on a specific, positive operational development (clinical trial success) intended for immediate public disclosure, it aligns best with the 'Earnings Release' category, which often encompasses key operational highlights outside of strict financial reporting periods, or potentially 'Regulatory Filings' (RNS) if it were less specific. Given the structure and content (announcing a key milestone that impacts future regulatory submissions and commercialization), ER is the most appropriate fit among the provided options for a major operational update press release. It is not a full report (10-K, IR), a transcript (CT), or a proxy statement (DEF 14A/PSI).
2023-08-11 English
Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" announcing that Photocure's partner, Asieris, confirmed a Phase III clinical trial for Hexvix in China met its endpoint. This is an announcement of a significant business/clinical development, not a formal regulatory filing like a 10-K, a comprehensive financial report like an IR, or a transcript. It is a general corporate announcement regarding clinical progress and regulatory submission plans. Since it doesn't fit the specific categories like ER (Earnings Release), LTR (Legal Proceedings), or CAP (Financing), the most appropriate general category for a significant, non-financial, non-governance corporate update that is not a standard report is Regulatory Filings (RNS), which serves as a broad category for important company news releases that don't fit elsewhere, although it is very close to an Investor Presentation (IP) in nature, it is structured as a press release announcing trial results and regulatory steps, making RNS the best fit among the provided options for a general corporate announcement of this nature.
2023-08-11 English
Photocure ASA: Results for the second quarter and first half of 2023
Earnings Release Classification · 99% confidence The document provides detailed financial highlights, operational reviews, and management commentary specifically for the 'second quarter 2023' and compares it to prior periods (Q2 2022, FY 2022, Q1 2023). It includes key performance indicators like revenue, EBITDA, unit sales, and guidance reiteration. This structure—a comprehensive review of a specific, shorter fiscal period (quarterly) with detailed segment breakdowns—is characteristic of an Interim/Quarterly Report (IR). While it contains elements that might appear in an Earnings Release (ER), the depth of the financial tables and operational review suggests it is more comprehensive than just the initial highlights, fitting the definition of an Interim Report (IR) better than a brief ER. Q2 2023
2023-08-09 English
Photocure ASA: Results for the second quarter and first half of 2023
Investor Presentation Classification · 99% confidence The document is explicitly titled "Photocure ASA 2nd Quarter 2023 Results" and contains detailed financial tables for Q2 '23 vs Q2 '22, including Income Statements, Revenue breakdowns by segment (North America, Europe), and operational highlights for the period. The content is comprehensive, covering performance, trends, and outlook for a specific fiscal period shorter than a year. This structure and content strongly indicate a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an Earnings Release (ER) which typically contains only highlights, nor is it the full Annual Report (10-K). The document is a presentation format, but its substance is the quarterly financial report itself.
2023-08-09 English
Photocure ASA: Results for the second quarter and first half of 2023
Earnings Release Classification · 100% confidence The document explicitly states it contains "Results for the second quarter and first half of 2023" and provides detailed financial metrics (revenues, EBITDA, EBIT) for the period ending Q2 2023. It also reiterates annual guidance. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The presence of detailed financial figures, management commentary, and specific period reporting (Q2/First Half) strongly points towards an Interim/Quarterly Report (IR). Although it mentions a presentation will be held, the core content provided is the results summary, not just an announcement of the report's release (which would be RPA/RNS). It is too detailed to be just an Earnings Release (ER). Q2 2023
2023-08-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.